Phase 1b/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with FOLFIRI plus /- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

被引：28
|
作者：
Bendel, Johanna C.
Hubbard, Joleen Marie
O'Neil, Bert H.
Jonker, Derek J.
Starodub, Alexander
Peyton, James D.
Pitot, Henry C.
Halfdanarson, Thorvardur Ragnar
Nadeau, Benjamin Rolland
Zubkus, John D.
Adesunloye, Bamidele
Edenfield, William Jeffery
Li, Youzhi
Li, Wei
Grothey, Axel
Borodyansky, Laura
Li, Chiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3529
引用
收藏
页数：5
相关论文
共 50 条
  • [21] CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC).
    Ziras, N.
    Polyzos, A.
    Xenidis, N.
    Kalykaki, A.
    Androulakis, N. E.
    Papakotoulas, P.
    Kentepozidis, N. K.
    Makrantonakis, P.
    Xynogalos, S.
    Sougklakos, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] A randomized phase II study comparing oral S-1 plus 24-hour infusion of irinotecan (Iri) and bevacizumab (Bev) with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (MCRC).
    Sadahiro, Sotaro
    Suzuki, Toshiyuki
    Tanaka, Akira
    Okada, Kazutake
    Saito, Gota
    Miyakita, Hiroshi
    Ogimi, Takashi
    Chan, Lin Fung
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [23] Liver and/or lung metastasectomy after cetuximab or bevacizumab plus FOLFIRI chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC).
    Kim, Sang-A
    Kim, Ji-Won
    Suh, Koung Jin
    Kim, Jin Won
    Oh, Heung-Kwon
    Cho, Jai Young
    Kim, Duck-Woo
    Lee, Keun-Wook
    Cho, Sukki
    Kim, Jee Hyun
    Kim, Kwhanmien
    Kang, Sung-Bum
    Jheon, Sanghoon
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [24] EVALUATION OF PANITUMUMAB (PMAB) PLUS FOLFIRI VERSUS FOLFIRI ALONE AS SECOND-LINE THERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING PRIOR BEVACIZUMAB (BEV) IN STUDY 20050181
    Peeters, Marc
    Price, Timothy
    Strickland, Andrew
    Ciuleanu, Tudor-Eliade
    Scheithauer, Werner
    O'Reilly, Seamus
    Keane, Maccon
    Spigel, David
    Tian, Ying
    Krishnan, Kartik
    ANNALS OF ONCOLOGY, 2011, 22 : v103 - v104
  • [25] Macrophage polarization related gene variants to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (bev) in combination with FOLFIRI.
    Sunakawa, Yu
    Stintzing, Sebastian
    Heinemann, Volker
    Loupakis, Fotios
    Cremolini, Chiara
    Cao, Shu
    Yang, Dongyun
    Zhang, Wu
    Parekh, Anish
    Yamauchi, Shinichi
    Ning, Yan
    Stremitzer, Stefan
    Matsusaka, Satoshi
    Mendez, Angela
    El-Khoueiry, Rita Elie
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [26] A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)
    Elez Fernandez, M. E.
    Rosello Keranen, S.
    Paez, D.
    Jimenez Castro, J.
    Rivera Herrero, F.
    Ruiz-Casado, A.
    Riesco Martinez, M. C.
    Montagut Viladot, C.
    Coupez, D.
    Ducreux, M. P.
    Loly, C.
    Martin-Babau, J.
    Prenen, H.
    van den Eynde, M.
    Borg, C.
    Cuyle, P-J.
    de Haar-Holleman, A.
    Raimbourg, J.
    Bechar, N.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S480 - S481
  • [27] A cost-effectiveness analysis of pretreatment DPYD and UGT1A1 screening in patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI plus bevacizumab (FOLFIRI plus Bev)
    Rivers, Zachary
    Stenehjem, David D.
    Jacobson, Pamala
    Lou, Emil
    Nelson, Andrew
    Kuntz, Karen M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [28] A phase Ib extension study of cancer sternness inhibitor BB608 (napabucasin) in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer.
    El-Rayes, Bassel F.
    Shanda, Safi
    Starodub, Alexander
    O'Neil, Bert H.
    Hanna, Wahid Tewfik
    Shaib, Walid Labib
    Oh, Cindy
    Li, Wei
    Li, Youzhi
    Borodyansky, Laura
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
    Wainberg, Zev A.
    Messersmith, Wells A.
    Peddi, Parvin F.
    Kapp, Amy V.
    Ashkenazi, Avi
    Royer-Joo, Stephanie
    Portera, Chia C.
    Kozloff, Mark F.
    CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 248 - 254
  • [30] Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Kasubhai, Saifuddin M.
    Bendell, Johanna C.
    Kozloff, Mark
    Kapp, Amy V.
    Ashkenazi, Avi
    Royer-Joo, Stephanie
    Portera, Chia C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345